title: [The therapeutic effects of highly active anti-retroviral therapy in 74 treatment-naive patients with AIDS in China].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of highly active anti-retroviral therapy (HAART) in treatment-naïve Chinese patients with AIDS, to provide evidences for standardizing HAART.
  
  
  METHODS
  Seventy-four treatment-naive AIDS patients were initiated with HAART and followed up regularly for 3 years. The clinical and laboratory data, side effects and drug resistance were observed and analyzed during the follow-up period.
  
  
  RESULTS
  Of the 74 patients, 46 were males and 28 were females, with the average age being 42 years. The mean HIV viral load was (2.2 ± 2.0) × 10(5) copies/ml and the baseline mean CD(4)(+)T lymphocyte count was (62 ± 71) cells/µl before treatment. After treatment for 3, 6, 12, 18, 24, 30 and 36 months, the percentage of undetectable HIV viral road (less than 50 copies/ml) was 71.6%, 83.8%, 75.7%, 77.0%, 82.4%, 81.1% and 79.7% respectively, and CD(4)(+)T lymphocyte count ascended to (167 ± 105), (177 ± 129), (238 ± 137), (290 ± 158), (304 ± 191), (331 ± 175) and (352 ± 202) cells/µl. The increase in amplitude of CD(4)(+)T lymphocyte count in different periods examined was different, with the period of 0-3 months post-treatment demonstrating the most obvious augmentation (P < 0.01). The most common adverse reactions were liver function injury (52/74, 70.3%), hyperlipemia (52/74, 70.3%), hematopoietic inhibition of the bone marrow (33/74, 44.6%), peripheral neuritis (32/74, 43.2%) and lipoatrophy (26/74, 35.1%). Clinical drug resistance were found in nine patients and HIV gene mutations were detected in these patients.
  
  
  CONCLUSIONS
  Chinese treatment-naive AIDS patients have achieved good virological and immunological response to generic-drug-predominant HAART regimes with low drug resistance, but relatively more side effects.
authors.affiliation: No 8 People's Hospital of Guangzhou, Guangzhou 510060, China.
authors.forename: Xie-jie
authors.initials: XJ
authors.lastname: Chen
authors.forename: Xiao-ping
authors.initials: XP
authors.lastname: Tang
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Cai
authors.forename: Jian-sheng
authors.initials: JS
authors.lastname: Zhang
authors.forename: Jin-feng
authors.initials: JF
authors.lastname: Chen
authors.forename: Qi-cai
authors.initials: QC
authors.lastname: Liu
authors.forename: Huo-lin
authors.initials: HL
authors.lastname: Zhong
authors.forename: Hao-lan
authors.initials: HL
authors.lastname: He
authors.forename: Ling-hua
authors.initials: LH
authors.lastname: Li
authors.forename: Bin
authors.initials: B
authors.lastname: Zhao
authors.forename: Hong
authors.initials: H
authors.lastname: Shang
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000821:virology; D000293:Adolescent; D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D002681:China; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult